Form 4: Exelixis Executive Awarded Performance-Based Restricted Stock Units

Amy C. Peterson, EVP of Product Development & Medical Affairs and CMO at Exelixis, Inc., received performance-based restricted stock units and disposed of common stock on March 31, 2025.

Summary

• Amy C. Peterson, an executive at Exelixis, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 31, 2025, Peterson was awarded 159,383 performance-based restricted stock units (PSUs) under the 2017 Equity Incentive Plan.
• These PSUs vest if the volume-weighted average closing price of Exelixis' common stock equals or exceeds $60 per share for 90 consecutive calendar days within a five-year period, and if Peterson remains employed through the fifth anniversary of the grant date.
• Peterson also disposed of 506,472 shares of common stock.
• Peterson beneficially owns 506,472 shares of common stock, including shares issuable upon the vesting of restricted stock units (RSUs) and PSUs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing executive compensation. It is neutral in sentiment.

Positives

• The award of PSUs to a key executive aligns their interests with the company's performance and long-term stock value appreciation.

Risks

• The vesting of the PSUs is contingent on achieving a specific stock price target, which may not be realized.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting conditions of the PSUs.

Industry Context

This filing is a routine disclosure of executive compensation and stock ownership changes, common in the biopharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages in the biopharmaceutical industry often include a mix of salary, stock options, restricted stock units, and performance-based incentives.
• The specific terms of the PSU award, such as the $60 stock price target and five-year vesting period, would need to be compared to similar awards at peer companies like Amgen, Gilead Sciences, or Biogen to assess its competitiveness.

Stakeholder Impact

• The PSU award incentivizes the executive to drive shareholder value by increasing the company's stock price.

Key Dates

Keywords

Form 4, beneficial ownership, restricted stock units, PSU, RSU, EXEL, Exelixis, Peterson, equity incentive plan